Ep. 210 Personalizing ADT Across the Prostate Cancer Spectrum with Dr. Rana McKay

419.651 - 444.138 Dr. Rana McKay

And for patients with very high risk disease defined as a PSA of greater than 40, at least an 8, 9, 10 disease or T3 disease, having two out of three of those factors, they're getting the addition of abiraterone to ADT. So that's treatment in the definitive setting with a curative intent. And we know that there are some patients that go on to relapse following definitive treatment.